Otso Arponen1,2, Amro Masarwah3,4, Anna Sutela3, Mikko Taina3,4, Mervi Könönen3, Reijo Sironen5,6,7, Juhana Hakumäki3, Ritva Vanninen3,4,7, Mazen Sudah3. 1. Kuopio University Hospital, Diagnostic Imaging Centre, Department of Clinical Radiology, Kuopio University Hospital, PO Box 1777, Puijonlaaksontie 2, 70210, Kuopio, Finland. otso.arponen@kuh.fi. 2. University of Eastern Finland, Institute of Clinical Medicine, School of Medicine, Department of Clinical Radiology, Kuopio University Hospital, PO Box 1777, Puijonlaaksontie 2, 70210, Kuopio, Finland. otso.arponen@kuh.fi. 3. Kuopio University Hospital, Diagnostic Imaging Centre, Department of Clinical Radiology, Kuopio University Hospital, PO Box 1777, Puijonlaaksontie 2, 70210, Kuopio, Finland. 4. University of Eastern Finland, Institute of Clinical Medicine, School of Medicine, Department of Clinical Radiology, Kuopio University Hospital, PO Box 1777, Puijonlaaksontie 2, 70210, Kuopio, Finland. 5. Kuopio University Hospital, Department of Pathology, Kuopio University Hospital, PO Box 1777, Puijonlaaksontie 2, 70210, Kuopio, Finland. 6. University of Eastern Finland, Institute of Clinical Medicine, School of Medicine, Clinical Pathology and Forensic Medicine, Kuopio University Hospital, PO Box 1777, Puijonlaaksontie 2, 70210, Kuopio, Finland. 7. University of Eastern Finland, Cancer Center of Eastern Finland, Yliopistonranta 1, 70210, Kuopio, Finland.
Abstract
OBJECTIVES: To evaluate the value of adding T2- and diffusion-weighted imaging (DWI) to the BI-RADS® classification in MRI-detected lesions. METHODS: This retrospective study included 112 consecutive patients who underwent 3.0T structural breast MRI with T2- and DWI on the basis of EUSOMA recommendations. Morphological and kinetic features, T2 signal intensity (T2 SI) and apparent diffusion coefficient (ADC) findings were assessed. RESULTS: Thirty-three (29.5 %) patients (mean age 57.0 ± 12.7 years) had 36 primarily MRI-detected incidental lesions of which 16 (44.4 %) proved to be malignant. No single morphological or kinetic feature was associated with malignancy. Both low T2 SI (P = 0.009) and low ADC values (≤0.87 × 10-3 mm2s-1, P < 0.001) yielded high specificity (80.0 %/80.0 %). The BI-RADS classification supplemented with information from DWI and T2-WI improved the diagnostic performance of the BI-RADS classification as sensitivity remained 100 % and specificity improved from 30 % to 65.0 %. The numbers of false positive lesions declined from 39 % (N = 14) to 19 % (N = 7). CONCLUSION: MRI-detected incidental lesions may be challenging to characterize as they have few specific malignancy indicating features. The specificity of MRI can be improved by incorporating T2 SI and ADC values into the BI-RADS assessment. KEY POINTS: • MRI-detected incidental lesions have few specific malignancy indicating features. • ≥ 1 suspicious morphologic or kinetic feature may warrant biopsy. • T2 signal intensity and DWI assessment are feasible in primarily MRI-detected lesions. • T2 SI and DWI assessment improve the BI-RADS specificity in MRI-detected lesions.
OBJECTIVES: To evaluate the value of adding T2- and diffusion-weighted imaging (DWI) to the BI-RADS® classification in MRI-detected lesions. METHODS: This retrospective study included 112 consecutive patients who underwent 3.0T structural breast MRI with T2- and DWI on the basis of EUSOMA recommendations. Morphological and kinetic features, T2 signal intensity (T2 SI) and apparent diffusion coefficient (ADC) findings were assessed. RESULTS: Thirty-three (29.5 %) patients (mean age 57.0 ± 12.7 years) had 36 primarily MRI-detected incidental lesions of which 16 (44.4 %) proved to be malignant. No single morphological or kinetic feature was associated with malignancy. Both low T2 SI (P = 0.009) and low ADC values (≤0.87 × 10-3 mm2s-1, P < 0.001) yielded high specificity (80.0 %/80.0 %). The BI-RADS classification supplemented with information from DWI and T2-WI improved the diagnostic performance of the BI-RADS classification as sensitivity remained 100 % and specificity improved from 30 % to 65.0 %. The numbers of false positive lesions declined from 39 % (N = 14) to 19 % (N = 7). CONCLUSION: MRI-detected incidental lesions may be challenging to characterize as they have few specific malignancy indicating features. The specificity of MRI can be improved by incorporating T2 SI and ADC values into the BI-RADS assessment. KEY POINTS: • MRI-detected incidental lesions have few specific malignancy indicating features. • ≥ 1 suspicious morphologic or kinetic feature may warrant biopsy. • T2 signal intensity and DWI assessment are feasible in primarily MRI-detected lesions. • T2 SI and DWI assessment improve the BI-RADS specificity in MRI-detected lesions.
Entities:
Keywords:
Breast cancer; DWI; Incidental MRI-detected lesions; Magnetic resonance imaging; T2
Authors: Pascal A T Baltzer; Matthias Benndorf; Matthias Dietzel; Mieczyslaw Gajda; Oumar Camara; Werner A Kaiser Journal: Eur Radiol Date: 2009-11-20 Impact factor: 5.315
Authors: Savannah C Partridge; Christiane D Mullins; Brenda F Kurland; Michael D Allain; Wendy B DeMartini; Peter R Eby; Constance D Lehman Journal: AJR Am J Roentgenol Date: 2010-06 Impact factor: 3.959
Authors: N H G M Peters; S van Esser; M A A J van den Bosch; R K Storm; P W Plaisier; T van Dalen; S C E Diepstraten; T Weits; P J Westenend; G Stapper; M A Fernandez-Gallardo; I H M Borel Rinkes; R van Hillegersberg; W P Th M Mali; P H M Peeters Journal: Eur J Cancer Date: 2010-12-30 Impact factor: 9.162
Authors: Manuel Debald; Alina Abramian; Lisa Nemes; Michael Döbler; Christina Kaiser; Mignon-Denise Keyver-Paik; Claudia Leutner; Tobias Höller; Michael Braun; Christiane Kuhl; Walther Kuhn; Hans H Schild Journal: Breast Cancer Res Treat Date: 2015-09-01 Impact factor: 4.872
Authors: Hiroyuki Abe; Robert A Schmidt; Rajshri N Shah; Akiko Shimauchi; Kirti Kulkarni; Charlene A Sennett; Gillian M Newstead Journal: AJR Am J Roentgenol Date: 2010-02 Impact factor: 3.959
Authors: Ceren Yalnız; Juliana Rosenblat; David Spak; Wei Wei; Marion Scoggins; Carisa Le-Petross; Mark J Dryden; Beatriz Adrada; Başak E Doğan Journal: Eur J Breast Health Date: 2019-10-01